Exposure to Guideline-Recommended Quadruple Therapy after First Hospitalisation for HFrEF in France

Clicks: 10
ID: 329719
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #68 of 80 articles by views in European Heart Journal Open

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction In 2021, the European Society of Cardiology updated its guidelines for managing heart failure with reduced left ventricular ejection fraction (HFrEF), recommending a four-drug regimen combining an SGLT2 inhibitor, a beta-blocker, a mineralocorticoid receptor antagonist, and a renin-angiotensin-aldosterone system inhibitor. This study assessed, six months after guideline publication, the exposure of this quadruple therapy in patients newly hospitalised for HFrEF and identified associated factors. Methods First-time hospitalisations for HFrEF in France in 2022 were identified using the French National Health Data System. Treatment exposure during the year following discharge was described. Logistic regression was used to assess factors associated with receiving quadruple therapy within 30 days, including socio-demographic characteristics, healthcare utilisation, and comorbidities. Results A total of 22,990 patients were included (65.1% men; mean age 74 years, SD 13.5). At 30 days, 26.3% of patients received quadruple therapy (22.5% at one year). Exposure rates were 76% for beta-blockers, 70% for renin-angiotensin-aldosterone system inhibitor, 58% for SGLT2 inhibitors, and 47% for mineralocorticoid receptor antagonists. Advanced age, female sex, and certain comorbidities were associated with a lower likelihood of receiving quadruple therapy, while early follow-up with a general practitioner or cardiologist increased this likelihood. Discussion Exposure of quadruple therapy remains limited, with challenges in both initiation and persistence over time. Older age and comorbidities would appear to constitute barriers. Further studies with longer follow-up after guideline publication are needed to assess temporal trends and the impact of strategies aimed at improving care.
Reference Key
openalex_W7214279977 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Gaël-Sean Marqueyssat, Audrey Dintilhac, Olivier Toulza, Philippe Cestac, Blandine Juillard‐Condat
Are you one of these authors? Claim your profile
Journal European Heart Journal Open
Year 2026
DOI
10.1093/ehjopen/oeag159
URL
https://doi.org/10.1093/ehjopen/oeag159
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.